Hippocampal atrophy rates in Alzheimer disease

Objective: To investigate the added value of hippocampal atrophy rates over whole brain volume measurements on MRI in patients with Alzheimer disease (AD), patients with mild cognitive impairment (MCI), and controls. Methods: We included 64 patients with AD (67 ± 9 years; F/M 38/26), 44 patients with MCI (71 ± 6 years; 21/23), and 34 controls (67 ± 9 years; 16/18). Two MR scans were performed (scan interval: 1.8 ± 0.7 years; 1.0 T), using a coronal three-dimensional T1-weighted gradient echo sequence. At follow-up, 3 controls and 23 patients with MCI had progressed to AD. Hippocampi were manually delineated at baseline. Hippocampal atrophy rates were calculated using regional, nonlinear fluid registration. Whole brain baseline volumes and atrophy rates were determined using automated segmentation and registration tools. Results: All MRI measures differed between groups (p < 0.005). For the distinction of MCI from controls, larger effect sizes of hippocampal measures were found compared to whole brain measures. Between MCI and AD, only whole brain atrophy rate differed significantly. Cox proportional hazards models (variables dichotomized by median) showed that within all patients without dementia, hippocampal baseline volume (hazard ratio [HR]: 5.7 [95% confidence interval: 1.5–22.2]), hippocampal atrophy rate (5.2 [1.9–14.3]), and whole brain atrophy rate (2.8 [1.1–7.2]) independently predicted progression to AD; the combination of low hippocampal volume and high atrophy rate yielded a HR of 61.1 (6.1–606.8). Within patients with MCI, only hippocampal baseline volume and atrophy rate predicted progression. Conclusion: Hippocampal measures, especially hippocampal atrophy rate, best discriminate mild cognitive impairment (MCI) from controls. Whole brain atrophy rate discriminates Alzheimer disease (AD) from MCI. Regional measures of hippocampal atrophy are the strongest predictors of progression to AD. AD = Alzheimer disease; BET = brain extraction tool; CI = confidence interval; df = degrees of freedom; FTLD = frontotemporal lobar degeneration; HR = hazard ratio; MCI = mild cognitive impairment; MMSE = Mini-Mental State Examination; NBV = normalized brain volume; PBVC = percentage brain volume change; ROI = region of interest; VaD = vascular dementia; VAT = visual association test.

[1]  M. Lawton,et al.  Assessment of older people: self-maintaining and instrumental activities of daily living. , 1969, The Gerontologist.

[2]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[3]  C. Jack,et al.  MRI‐Based Hippocampal Volume Measurements in Epilepsy , 1994, Epilepsia.

[4]  K. Jellinger,et al.  Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. , 1996, Neurology.

[5]  Nick C Fox,et al.  Brain atrophy progression measured from registered serial MRI: Validation and application to alzheimer's disease , 1997, Journal of magnetic resonance imaging : JMRI.

[6]  Nick C Fox,et al.  Interactive algorithms for the segmentation and quantitation of 3-D MRI brain scans. , 1997, Computer methods and programs in biomedicine.

[7]  Nick C Fox,et al.  Modeling brain deformations in Alzheimer disease by fluid registration of serial 3D MR images. , 1998, Journal of computer assisted tomography.

[8]  R. Faber,et al.  Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. , 1999, Neurology.

[9]  C. Jack,et al.  Rates of hippocampal atrophy correlate with change in clinical status in aging and AD , 2000, Neurology.

[10]  Nick C. Fox,et al.  Automated Hippocampal Segmentation by Regional Fluid Registration of Serial MRI: Validation and Application in Alzheimer's Disease , 2001, NeuroImage.

[11]  M N Rossor,et al.  Progressive brain atrophy on serial MRI in dementia with Lewy bodies, AD, and vascular dementia , 2001, Neurology.

[12]  J Mazziotta,et al.  A probabilistic atlas and reference system for the human brain: International Consortium for Brain Mapping (ICBM). , 2001, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[13]  J. Morris,et al.  Current concepts in mild cognitive impairment. , 2001, Archives of neurology.

[14]  Nick C Fox,et al.  Mapping the evolution of regional atrophy in Alzheimer's disease: Unbiased analysis of fluid-registered serial MRI , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[15]  B Schmand,et al.  Visual association test to detect early dementia of the Alzheimer type , 2002, Journal of neurology, neurosurgery, and psychiatry.

[16]  Stephen M. Smith,et al.  Accurate, Robust, and Automated Longitudinal and Cross-Sectional Brain Change Analysis , 2002, NeuroImage.

[17]  N. Schuff,et al.  Comparison of methods for measuring longitudinal brain change in cognitive impairment and dementia , 2003, Neurobiology of Aging.

[18]  Henrik Zetterberg,et al.  Cerebrospinal fluid markers for prediction of Alzheimer's disease , 2003, Neuroscience Letters.

[19]  Nick C Fox,et al.  Assessing the onset of structural change in familial Alzheimer's disease , 2003, Annals of neurology.

[20]  Henry Rusinek,et al.  Regional brain atrophy rate predicts future cognitive decline: 6-year longitudinal MR imaging study of normal aging. , 2003, Radiology.

[21]  W. M. van der Flier,et al.  Volumetric MRI predicts rate of cognitive decline related to AD and cerebrovascular disease , 2003, Neurology.

[22]  Nick C Fox,et al.  Change in rates of cerebral atrophy over time in early-onset Alzheimer's disease: longitudinal MRI study , 2003, The Lancet.

[23]  Nick C. Fox,et al.  Global and local gray matter loss in mild cognitive impairment and Alzheimer's disease , 2004, NeuroImage.

[24]  R. Petersen.  Mild cognitive impairment as a diagnostic entity , 2004, Journal of internal medicine.

[25]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[26]  F. Woermann,et al.  Transient lesion in the splenium of the corpus callosum and antiepileptic drug withdrawal , 2005, Neurology.

[27]  C. Jack,et al.  Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI , 2005, Neurology.

[28]  R. Buckner,et al.  Normative estimates of cross-sectional and longitudinal brain volume decline in aging and AD , 2005, Neurology.

[29]  Nick C Fox,et al.  Baseline predictors of rates of hippocampal atrophy in mild cognitive impairment , 2007, Neurology.

[30]  R. Mayeux,et al.  Hippocampal and entorhinal atrophy in mild cognitive impairment , 2007, Neurology.

[31]  Nick C. Fox,et al.  Improved reliability of hippocampal atrophy rate measurement in mild cognitive impairment using fluid registration , 2007, NeuroImage.

[32]  Nick C. Fox,et al.  Automated Measurement of Hippocampal Atrophy Using Fluid-Registered Serial MRI in AD and Controls , 2007 .

[33]  C. Jack,et al.  3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer's disease. , 2007, Brain : a journal of neurology.

[34]  C. Jack,et al.  Atrophy rates accelerate in amnestic mild cognitive impairment , 2008, Neurology.

[35]  C. Jack,et al.  MRI patterns of atrophy associated with progression to AD in amnestic mild cognitive impairment , 2008, Neurology.

[36]  Nick C Fox,et al.  Volumetric MRI and cognitive measures in Alzheimer disease , 2008, Journal of Neurology.

[37]  Frederik Barkhof,et al.  Whole-brain atrophy rate and cognitive decline: longitudinal MR study of memory clinic patients. , 2008, Radiology.

[38]  Nick C. Fox,et al.  A meta-analysis of hippocampal atrophy rates in Alzheimer's disease , 2009, Neurobiology of Aging.

[39]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.